Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$119.35 USD
-0.40 (-0.33%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $119.32 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zimmer Biomet (ZBH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$134.65 | $155.00 | $99.00 | 12.44% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Zimmer Biomet comes to $134.65. The forecasts range from a low of $99.00 to a high of $155.00. The average price target represents an increase of 12.44% from the last closing price of $119.75.
Analyst Price Targets (23)
Broker Rating
Zimmer Biomet currently has an average brokerage recommendation (ABR) of 2.52 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 2.52 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 28% and 8% of all recommendations. A month ago, Strong Buy made up 28%, while Buy represented 8%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 14 | 14 | 14 | 14 | 13 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.52 | 2.52 | 2.52 | 2.52 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
2/28/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
2/23/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
1/15/2024 | Needham & Company | Michael Matson | Not Available | Hold |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
12/22/2023 | Truist Securities | Richard Newitter | Hold | Hold |
11/13/2023 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
11/9/2023 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
11/7/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/21/2023 | Roth Capital Partners | Jason Wittes | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.52 |
ABR (Last week) | 2.52 |
# of Recs in ABR | 25 |
Average Target Price | $134.65 |
LT Growth Rate | 6.70% |
Industry | Medical - Products |
Industry Rank by ABR | 140 of 252 |
Current Quarter EPS Est: | 1.88 |